Stratum Nutrition and KD Pharma created a partnership to develop a joint-health formula, MOVE3, combining Stratum's NEM brand eggshell membrane and KD Pharma's marine omega oils KD-Pür.
Photo © iStockphoto.com/peepo
Stratum Nutrition (Carthage, MO) and KD Pharma (Bexbach, Saarland, Germany) created a partnership to develop a joint-health formula, MOVE3, combining Stratum's NEM brand eggshell membrane and KD Pharma's marine omega oils KD-Pür. Moreover, a recent study evaluated the ingredient’s effect on joint pain and stiffness after exercise.
The randomized, double-blind, placebo-controlled study, published in the International Journal of Physical Medicine and Rehabilitation, evaluated whether MOVE3 versus a placebo would reduce cartilage turnover and alleviate joint pain and/or stiffness immediately following exercise and 12 hours post exercise. A total of 85 healthy men and women (40-70 years) were randomly assigned to receive either 500 mg/d of eggshell membrane with 1,500 mg fish oil concentrate (n=43) or 2,000 mg/d of a placebo (n=42).
MOVE3 produced statistically significant reductions in levels of urinary excretion of C-terminal cross-linked telopeptide of type-II collagen (uCTX-II), a marker of cartilage degradation, versus the placebo after one and two weeks of exercise. Compared with the placebo, MOVE3 also significantly relieved joint pain immediately after exercise at one week, pain 12 hours after exercise at one week, and stiffness 12 hours after exercise at one week.
"The body of science supporting exercise and recovery benefits for both omega-3 and NEM continues to grow, but this study is unique because it demonstrates benefits in healthy people consuming the MOVE3 formulation after they have exercised," said Adam Ismail, chief strategy officer of KD Pharma Group, in a press release. "For sports nutrition products, it is important that consumers be able to feel the benefit, and the fact that we saw a significant improvement compared to placebo means the subjects not only felt the impact of MOVE3 but observed the effects in a rapid timeframe."
Kevin Ruff, PhD, MBA, senior director of scientific & regulatory affairs for Stratum Nutrition, added: "Conducting this clinical trial in exercising healthy adults will allow brands to make label claims relating to joint pain and stiffness and even cartilage protection. This is an additional benefit that MOVE3 provides beyond any other combination product on the market."
Reference
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.